Mithra logo.jpg
Mithra Pharmaceuticals - Payment of the interests of the Highbridge/Whitebox loans Information on the total number of voting rights (denominator)
May 12, 2023 11:45 ET | Mithra Pharmaceuticals
Payment of the interests of the Highbridge/Whitebox loans Information on the total number of voting rights (denominator) Liege, Belgium, 12 May 2023 – 17:50 CET – Mithra Pharmaceuticals SA...
Mithra logo.jpg
Mithra Announces Completion of Recruitment in Pediatric Study of Estelle in Adolescent Patients
May 11, 2023 01:30 ET | Mithra Pharmaceuticals
Mithra Announces Completion of Recruitment in Pediatric Study of Estelle in Adolescent Patients Trial designed to address limited clinical data in this population despite widespread use of Combined...
Mithra logo.jpg
Mithra and the University of Liège Secure Proof-of-Concept for Novel Manufacturing Process of Estetrol
May 04, 2023 01:30 ET | Mithra Pharmaceuticals
Collaboration demonstrates Mithra’s commitment to innovation and sustainable drug supply in Women’s Health Liege, Belgium, 04 May 2023 – 7:30 CEST – Mithra (Euronext Brussels: MITRA), a company...
Mithra logo.jpg
Publication of a transparency notification received from Alychlo NV
April 28, 2023 11:45 ET | Mithra Pharmaceuticals
Liege, Belgium, 28 April 2023 – 17:45 CEST – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, today announces, in accordance with Article 14 of the Belgian Law of 2 May 2007...
Mithra annonce ses r
Mithra annonce ses résultats annuels 2018
March 01, 2019 07:00 ET | Mithra Pharmaceuticals
Mithra annonce ses résultats annuels 2018 Forte croissance du chiffre d'affaires (+42%) et amélioration significative de l'EBITDA qui atteint un niveau record (38,3 millions EUR contre -18,4...
Mithra Reports 2018
Mithra Reports 2018 Annual Results
March 01, 2019 07:00 ET | Mithra Pharmaceuticals
Mithra Reports 2018 Annual Results Strong revenue growth (+42%) with significantly improved EBITDA (record level of EUR 38.3 M vs. EUR -18.4 M in 2017) and cash position (EUR 119 M vs. EUR 36.2 M...
logo (1).jpg
Mithra Announces Positive Top-line Results of Estelle® Phase III Oral Contraceptive Study in U.S/Canada
January 30, 2019 07:00 ET | Mithra Pharmaceuticals
Mithra Announces Positive Top-line Results of Estelle® Phase III Oral Contraceptive Study in U.S/Canada Primary efficacy endpoint indicates excellent contraceptive efficacy, with a Pearl Index...